Pacific Biosciences of California (PACB)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $574.52M
Last updated: Nov 17, 2026 at 4:42 PM ET
Pacific Biosciences of California (PACB) Statistics
Pacific Biosciences of California (PACB) has a market cap of $574.52M and an enterprise value of $1.16B. It kept -81.31% of revenue as net income over the last 12 months. Its net debt of $587.15M equals 102.20% of its market cap.
Total Valuation
Enterprise value is 102.20% above the market cap, as debt exceeds cash.
| Market Cap | $574.52M |
|---|---|
| Enterprise Value | $1.16B |
| Latest price (Nov 17, 2026) | $1.82 |
Key Dates
The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 9, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 3.5x. Its year-end P/S ranged from 3.0x to 56.4x from 2016 to 2025.
| P/S Ratio | 3.5x |
|---|---|
| Forward P/S | 3.6x |
Price Statistics
The stock is up 13.04% over 52 weeks and trades 9.90% below its 50-day average.
| Beta (1Y) | 2.14 |
|---|---|
| 52-Week Change | +13.04% |
| 1-Month Change | -1.09% |
| 3-Month Change | +43.31% |
| 6-Month Change | +58.26% |
| 5-Year Change | -90.16% |
| 10-Year Change | -69.35% |
| Total Return (1Y) | +13.04% |
| Total Return (3Y CAGR) | -39.93% |
| Total Return (5Y CAGR) | -40.89% |
| Return vs SPY (1Y) | -1.26% |
| Max Drawdown (1Y) | -58.43% |
| Max Drawdown (3Y) | -91.21% |
| Sharpe Ratio (1Y) | 0.11 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $2.02 |
| 200-Day Average | $1.60 |
| 52-Week Range | $1.07 to $3.44 |
| RSI (14 Days) | 39.8 |
| Average Volume (20 Days) | 13.02M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.62x current liabilities.
| Current Ratio | 4.62x |
|---|---|
| Quick Ratio | 3.72x |
| Interest Coverage | -16.07x |
Returns and Efficiency
Return on invested capital is -21.12% over the last 12 months, against a 5-year average of -35.87%.
| Return on Assets (ROA) | -18.20% |
|---|---|
| Return on Invested Capital (ROIC) | -21.12% |
| Return on Capital Employed (ROCE) | -18.77% |
| ROA (5Y Average) | -27.73% |
| ROIC (5Y Average) | -35.87% |
| Asset Turnover | 0.21x |
| Inventory Turnover | 1.74x |
| Receivables Turnover | 4.65x |
| Cash Conversion Cycle | 236 days |
Scores
PACB has an Altman Z-Score of -4.91, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -4.91 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $161.39M over the last 12 months is up 4.41% from the 12 months before.
| Revenue | $161.39M |
|---|---|
| Revenue Growth (YoY) | +4.41% |
| Gross Profit | $55.52M |
| Operating Income | -$131.17M |
| Pretax Income | -$130.52M |
| Net Income | -$131.23M |
| EBITDA | -$105.33M |
| EBIT | -$122.87M |
| Reported EPS (TTM) | -$0.49 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $55.91M |
|---|---|
| Total Debt | $643.06M |
| Net Debt | $587.15M |
| Net Debt Per Share | $1.89 |
| Working Capital | $241.26M |
| Shareholder Equity | -$61.38M |
| Tangible Book Value | -$391.31M |
| Total Assets | $721.10M |
| Total Liabilities | $782.48M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $6.45M of capital spending, operating cash flow left -$143.40M of free cash flow.
| Operating Cash Flow | -$136.95M |
|---|---|
| Capital Expenditures | $6.45M |
| Free Cash Flow | -$143.40M |
| FCF Per Share | -$0.46 |
| Depreciation and Amortization | $17.54M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -81.27%.
| Gross Margin | 34.40% |
|---|---|
| Operating Margin | -81.27% |
| Pretax Margin | -80.87% |
| Net Margin | -81.31% |
| EBITDA Margin | -65.26% |
| EBIT Margin | -76.13% |
| FCF Margin | -88.85% |
| Gross Margin (5Y Average) | 32.49% |
Growth
Revenue grew 7.64% a year over 3 years.
| Revenue Growth (3Y CAGR) | +7.64% |
|---|---|
| Revenue Growth (5Y CAGR) | +15.19% |
| Book Value Per Share Growth (2Y CAGR) | -91.79% |
Dividends and Yields
PACB does not pay a dividend. Its free cash flow yield is -25.31%.
| FCF Yield | -25.31% |
|---|---|
| Buyback Yield | -0.56% |
| Shareholder Yield | -0.56% |
Peer Position
Against 12 similar companies, PACB has the 8th highest P/S.
P/S RatioPeer median 4.3x
ROICPeer median -17.35%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +14.20%
| P/S Ratio | 3.5x vs 4.3x median |
|---|---|
| ROIC | -21.12% vs -17.35% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +4.41% vs +14.20% median |
Analyst Forecast
Consensus estimates put revenue growth at 5.50% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +5.50% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PACB
What is PACB's market cap?
Pacific Biosciences of California has a market cap of $574.52M. Its enterprise value, which adds debt and subtracts cash, is $1.16B.
How many shares of PACB are outstanding?
Pacific Biosciences of California has 311.25M shares outstanding. The count is up 3.46% from a year earlier.
Does PACB pay a dividend?
No. Pacific Biosciences of California does not pay a dividend.
How much debt does PACB have?
Pacific Biosciences of California has $643.06M of total debt and $55.91M of cash and equivalents, a net debt position of $587.15M.
PACB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors, Government Contracts